Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LEISHDNAVAX
- Development stage
- Preclinical
- Lead developer
- Mologen
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
**LEISHDNAVAX** is a preclinical pentavalent DNA vaccine candidate for prevention and potential immunotherapy of human visceral and cutaneous leishmaniasis. Developed using MIDGE-Th1 minimalistic gene-expression vectors, it is an equimass mixture of five vectors encoding T-cell-epitope-enriched *Leishmania* antigens: kinetoplastid membrane protein-11, cysteine proteinase type II, cysteine proteinase type I, elongation factor 1-alpha, and thiol-specific antioxidant. Intradermal administration is intended to induce antigen-specific CD4-positive and CD8-positive T-cell responses, including a protective Th1-biased cellular immune response against intracellular *Leishmania* parasites. Preclinical studies reported immunogenicity, protection in rodent visceral-leishmaniasis models, and an acceptable repeated-dose safety profile in mice and rats. ([nature.com](https://www.nature.com/articles/gt201535.pdf))
- Other names
- MIDGE-based leishmaniasis vaccine
02
Targets
Clostridium perfringens toxinKMP-11 (Kinetoplastid membrane protein 11)DYNC1I1 (Cytoplasmic dynein 1 intermediate chain 1)PRDX (Peroxiredoxin family)CPB (Cysteine proteinase B)EEF1A1 (Elongation Factor 1 Alpha)
Beyond the preview
Go deeper on LEISHDNAVAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LEISHDNAVAX.